Eliem Therapeutics

Boston, United States Founded: 2018 • Age: 8 yrs Listed
Develops antibody-based treatments for autoimmune and inflammatory disorders.

About Eliem Therapeutics

Eliem Therapeutics is a Healthcare company based in Boston (United States) founded in 2018 by Valerie Morisset and Andrew Levin. It develops antibody-based treatments for autoimmune and inflammatory disorders. It operates on a B2B model. Eliem Therapeutics has raised $171.3 million across 5 funding rounds from investors including RA Capital, ICG and LifeArc. The company has 30 employees. Eliem Therapeutics has completed 1 acquisition, including Tenet Medicines. Eliem Therapeutics offers products and services including Budoprutug. Its focus areas include Biopharmaceuticals, Autoimmune Diseases, Inflammatory Therapeutics and Biotech. Its legal entity is Eliem Therapeutics, Inc. Its competitors include Flexion Therapeutics, Cara Therapeutics and Zogenix; 3 of its 3 listed competitors have raised funding.

Company details

Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on creating therapeutics for autoimmune-driven inflammatory diseases. They advance treatments like budoprutug, an anti-CD19 antibody that depletes B cells to reduce autoantibodies. Operating from locations in the US and UK, they conduct clinical trials for conditions such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy, collaborating with experts in biotechnology.

  • Headquarters Boston, United States
  • Employees 30
  • Founders Valerie Morisset, Andrew Levin
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website eliemtx.com
  • Social LinkedIn
  • Legal Name Eliem Therapeutics, Inc.
Key Metrics
  • Total Equity Funding
    $171.3M (USD)

    in 5 rounds

  • Latest Funding Round
    $60M (USD), Series C

    May 2021

  • Investors
    RA Capital

    & 5 more

  • Employee Count
    30
  • Investments & Acquisitions

Products & Services of Eliem Therapeutics

Eliem Therapeutics offers a comprehensive portfolio of products and services, including Budoprutug.

Budoprutug
Therapeutic Antibody

Anti-CD19 antibody to deplete B cells and reduce autoantibodies.

Funding Insights of Eliem Therapeutics

Eliem Therapeutics has successfully raised a total of $171.3M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $60 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $171.3M
  • Total Rounds 5
  • Last Round Series C β€” $60M
  • First Round $16.3M

    (Feb 2019)

  • Investors Count 6

All 5 funding rounds of Eliem Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2021$60MSeries C––
–
Mar 2021$80MSeries C–RA Capital Management, ICG
Oct 2020$5MSeries B––
–
Oct 2019$10MSeries B––
–
Feb 2019$16.3MSeries B––
–
Valuation history

6 investors in total: 6 institutional.

Investors in Eliem Therapeutics

Eliem Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, ICG and LifeArc.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
ICG is recognized as a global alternative asset manager.
1989icgam.comLondon, United Kingdom
acornbioventures.com
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
2004racap.comBoston, United States
Access Biotechnology is engaged in investing in transformative biopharma therapies.
1986accessbio-tech.comNew York, United States
Offers secure online access to investment materials for authorized users only.
2006samlyncapital.comNew York, United States
Medical research and treatments are supported by the community foundation.
1992lifearc.orgLondon, United Kingdom
Premium access

Investor details for Eliem Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Eliem Therapeutics

12 people are tracked at Eliem Therapeutics (7 in leadership, 4 in board & advisors, 1 in team); the tracked headcount is 30.

NameRoleGroup
Valerie Morisset
Co-FounderLeadership
Andrew Levin
Co-FounderLeadership
Nicholas Nebbeling
Controller/director Of AccountingLeadership
Jo Palmer-Phillips
Chief Development OfficerLeadership
Bob Azelby
President & CEOLeadership
Susan Franks
SVP & Head of Regulatory AffairsLeadership
Emily Pimblett, CPA
Vice President Of AccountingLeadership
Simon Tate
DirectorBoard & advisors
Judith Dunn
DirectorBoard & advisors
Liam Ratcliffe
DirectorBoard & advisors
Adam Rosenberg
DirectorBoard & advisors
Cheryl T.
Staff AccountantTeam
Premium access

Complete people profiles for Eliem Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Eliem Therapeutics

Eliem Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tenet Medicines.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Therapeutics for autoimmune-driven inflammatory diseases are developed.
Scotch Plains, United States2023Apr 2024β€’β€’β€’β€’
Premium access

Complete acquisition details for Eliem Therapeutics

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Eliem Therapeutics

5 dated milestones of Eliem Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Eliem Therapeutics is founded.
  2. Funding First funding round of $16.3M.
  3. Funding Latest funding round, Series C, of $60.0M.
  4. IPO Lists on the stock exchange (IPO).
  5. Acquisition Acquires Tenet Medicines.

Competitors of Eliem Therapeutics

Eliem Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Cara Therapeutics and Zogenix.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
flexiontherapeutics.com2007Woburn, United States$62M692
Developer of therapies for the treatment of musculoskeletal disorders
caratherapeutics.com2004New York, United States$51M79
Developer of therapeutics for pain relief and inflammatory diseases
zogenix.com2006Emeryville, United States$149.06M159
Drug delivery systems for CNS disorders and pain are developed.
Premium access

Detailed competitors of Eliem Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Eliem Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Eliem Therapeutics

Premium access

Complete news archive for Eliem Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Eliem Therapeutics

Eliem Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Eliem Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Eliem Therapeutics is a funded company, having raised a total of $171.3M across 5 funding rounds to date. The company's 1st funding round was a Series B of $16.3M, raised on Feb 2019.

Eliem Therapeutics has 30 employees.

Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on creating therapeutics for autoimmune-driven inflammatory diseases. They advance treatments like budoprutug, an anti-CD19 antibody that depletes B cells to reduce autoantibodies. Operating from locations in the US and UK, they conduct clinical trials for conditions such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy, collaborating with experts in biotechnology.

Eliem Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Zogenix.

Eliem Therapeutics offers Budoprutug.

Eliem Therapeutics has made 1 acquisition, including Tenet Medicines.

Eliem Therapeutics has 6 investors. Key investors include RA Capital, ICG, LifeArc, Access Biotechnology, and Samlyn Capital.

Eliem Therapeutics operates through Eliem Therapeutics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available